Carl Ash
DePauw University
6 Papers
2 Citations
Carl Ash is an academic researcher from DePauw University. The author has contributed to research in topics: Dopaminergic & Neuroprotection. The author has an hindex of 1, co-authored 3 publications. Previous affiliations of Carl Ash include Indiana University.
Chat about Author
Papers
Comprehensive Evaluation of the 5XFAD Mouse Model for Preclinical Testing Applications: A MODEL-AD Study.
Adrian L. Oblak,Peter Bor-Chian Lin,Kevin P. Kotredes,Ravi S. Pandey,Dylan Garceau,Harriet M. Williams,Asli Uyar,Rita O'Rourke,Sarah O'Rourke,Cynthia M. Ingraham,Daria Bednarczyk,Melisa Belanger,Zackary A. Cope,Gabriela J. Little,Sean-Paul G. Williams,Carl Ash,Adam Bleckert,Tim Ragan,Benjamin A. Logsdon,Lara M. Mangravite,Stacey J. Sukoff Rizzo,Paul R. Territo,Gregory W. Carter,Gareth R. Howell,Michael Sasner,Bruce T. Lamb +25 more
TL;DR: In this paper, a detailed characterization of the 5XFAD mouse was conducted, including transcriptomics, electroencephalogram, in vivo imaging, biochemical characterization, and behavioral assessments.
Problematic smartphone use: The role of reward processing, depressive symptoms and self-control.
TL;DR: In this paper, the authors examined the association between problematic smartphone use and event-related potentials (ERPs) related to reward processing and determined whether reward processing, depressive symptoms and self-control have shared or unique influences on problematic smartphone usage.
23
Smartphone Pathology, Agency and Reward Processing
Bridget Kirby,Ashley Dapore,Carl Ash,Kaitlyn Malley,Robert West +4 more
- 02 Jun 2020
TL;DR: This paper examined the relationship between pathological smartphone use and the neural correlates of reward processing in a college-aged sample and found that the amplitude of neural activity elicited by gains and losses was negatively correlated with pathological smartphone usage.
3
Identification of Small Molecule Therapeutics and Neuroprotective Gene Targets via High Throughput Screening and RNA Interference inC. elegansParkinson’s Disease Models
Carl Ash,Emily E. Anderson,Amy E. Moritz,Patricia Dranchak,R. Benjamin Free,James Inglese,Joseph P. Steiner,David R. Sibley,Emmanuel Akano +8 more
TL;DR: In this article , the authors used RNA interference (RNAi) to identify small molecule compounds with therapeutic potential and for probing genes potentially involved in dopaminergic neuroprotection in worms with Parkinson's disease.
Establishing an RNA interference (RNAi) screen for neuroprotection of dopaminergic neurons in Caenorhabditis elegans models of Parkinson’s disease
Emily E. Anderson,Carl Ash,Amy E. Moritz,Patricia Dranchak,R. Benjamin Free,James Inglese,Joseph P. Steiner,David R. Sibley,Emmanuel Akano +8 more
TL;DR: It is established that these models recapitulate the age‐dependent degeneration of dopaminergic neurons observed in human PD and may also identify genes encoding druggable targets for therapeutics directed at slowing the progression of PD.